Wendy L Dixon
CIK 1202283 · last filed 2025-05-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
INCY price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ZVRA | Director | — | $10.33 | — | $0 | 3 | 2025-05-30 |
| BDTX | Director | 38,054 | $2.08 | $79.2K | $0 | 12 | 2024-04-03 |
| ARVN | Director | 9,121 | $7.72 | $70.4K | $0 | 4 | 2023-06-20 |
| ALKS | Director | 53,124 | $44.18 | $2.35M | -$1.05M | 21 | 2022-06-16 |
| IOVA | Director | — | $14.14 | — | $0 | 1 | 2022-06-14 |
| INCY | Director | 17,768 | $116.93 | $2.08M | -$6.71M | 43 | 2022-04-04 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 595 | $4.97 | $3.0K | $0 | 8 | 2021-11-17 |
| VYGR | Director | — | $1.86 | — | $0 | 5 | 2020-06-05 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | — | $12.58 | — | $0 | 2 | 2019-06-21 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | — | — | — | $0 | 4 | 2017-05-23 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | Director | — | — | — | $0 | 6 | 2015-06-10 |
| Furiex Pharmaceuticals, Inc. (FURX) Delisted | Director | 7,160 | — | — | $0 | 7 | 2014-03-04 |
| Ardea Biosciences, Inc./DE (RDEA) Delisted | Director | — | — | — | $0 | 3 | 2012-06-20 |
Recent Filings · Page 5 of 15
145 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-07-01 | ARVN | Grant (A) | — | $0 | EDGAR |
| 2020-06-22 | bluebird bio, Inc. (BLUE) Delisted | Grant (A) | +1,653 | $0 | EDGAR |
| 2020-06-05 | VYGR | Grant (A) | — | $0 | EDGAR |
| 2020-05-28 | INCY | Grant (A) | +1,282 | $0 | EDGAR |
| 2020-05-22 | ALKS | Grant (A) | — | $0 | EDGAR |
| 2020-04-02 | INCY | Grant (A) | +243 | $17.8K | EDGAR |
| 2020-01-03 | INCY | Grant (A) | +196 | $17.1K | EDGAR |
| 2019-11-08 | INCY | Mixed | — | -$3.81M | EDGAR |
| 2019-10-02 | INCY | Grant (A) | +225 | $16.7K | EDGAR |
| 2019-07-02 | INCY | Grant (A) | +208 | $17.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.